SATRI-CEL ELIGIBILITY
My gastric / GEJ cancer has progressed, I am HER2-negative and CLDN18.2-positive. Could satri-cel be worth a formal review?
Possibly. Satri-cel may be relevant to selected patients with later-line advanced gastric or gastroesophageal-junction cancer that is HER2-negative and CLDN18.2-positive, but a formal review is not a commitment to treatment or travel. Current U.S. standard options and realistically executable U.S. trials should be screened first; if no clearly preferable local route remains, a licensed destination treating center can review the case remotely before any travel decision. If a better U.S. option exists, stopping here is the right outcome.
Four answers to verify first
Is satri-cel the same treatment as CT041?
Yes. Satri-cel is satricabtagene autoleucel, the CLDN18.2-targeted CAR-T therapy developed under the investigational code CT041. The pivotal randomized phase 2 study was CT041-ST-01.
Is satri-cel approved or currently enrolling patients in the United States?
No U.S. commercial approval is in place. The North American CT041 study NCT04404595 is closed to new accrual; NCI lists the trial as closed to accrual. That makes a local U.S. standard-treatment and realistically executable trial screen the first step before considering an overseas review.
Why does the CLDN18.2 40% threshold matter for satri-cel?
In the randomized phase 2 satri-cel study, CLDN18.2 positivity was defined as immunohistochemistry intensity of at least 2+ in at least 40% of tumor cells. A treating center still determines whether an individual pathology result is adequate for clinical review; a binary “positive” label alone is not enough.
Do I need to travel to China before a satri-cel review?
No. A destination treating team can first review records remotely. A formal review is not a commitment to treatment or travel. Travel should be considered only after the case has been reviewed, the treating team has identified a viable route, and the patient understands the clinical and practical requirements.
What satri-cel is — and what approval does not mean
Satricabtagene autoleucel (satri-cel) is a China-approved, CLDN18.2-targeted autologous CAR-T therapy for selected advanced gastric or gastroesophageal-junction (GEJ) adenocarcinoma. China approval establishes a regulatory pathway there; it does not establish patient-specific eligibility, travel readiness, treating-center acceptance, or a treatment timeline.
When a formal review may be worth considering
A formal review may be worth considering when disease has progressed, HER2 is negative, the CLDN18.2 result is interpretable and treatment-relevant, the case is later-line, current U.S. approved options and realistically executable trials have been screened, no clearly preferable local route remains, the patient is clinically stable enough for review and possible travel, and the patient has opted in to an overseas review.
When to stop rather than proceed
Do not treat an overseas review as the next step when a clearly preferable and executable U.S. route exists, the biomarker result is unknown or incomplete, the patient is clinically unstable or needs emergency care, or the patient expects a guaranteed acceptance or treatment outcome. Vialen organizes the access pathway and record-readiness process; licensed treating physicians and institutions determine eligibility, treatment, monitoring and other medical decisions.
The local-option check comes first
Before any China pathway is discussed, current U.S. standard treatment and realistically executable U.S. trials should be screened. ASCO’s July 2026 living guideline recommends early biomarker-directed decision-making in advanced gastroesophageal cancer, including HER2, PD-L1, MMR/MSI and CLDN18.2, with U.S. standard therapy selected from that profile before any overseas pathway is considered. Do not book travel before a destination treating team has reviewed the case and accepted it in writing. The decision sequence is: PROGRESSION → HER2 / CLDN18.2 STATE → U.S. STANDARD/TRIAL SCREEN → RECORD READINESS → REMOTE DESTINATION REVIEW → ACCEPT / STOP → TRAVEL DECISION.
Records needed before formal review
Prepare the pathology report (including CLDN18.2 staining percentage and intensity if available), HER2 result, prior treatment lines and dates, latest imaging showing current disease/progression, a concise oncology treatment summary, and current clinical status. If CLDN18.2 status is unknown or incomplete, pathology retrieval or testing through normal clinical care comes before destination planning.
Primary sources checked
Vialen uses primary regulatory and clinical sources for the factual gate below; these sources do not determine an individual patient’s eligibility.
Get my satri-cel treatment options →
Last reviewed: September 13, 2026 · Related